Herbert, S. L. http://orcid.org/0000-0002-5810-9055
Wöckel, A.
Kreienberg, R.
Kühn, T.
Flock, F.
Felberbaum, R.
Janni, W.
Curtaz, C.
Kiesel, M.
Stüber, T.
Diessner, J.
Salmen, J.
Schwentner, L.
Fink, V.
Bekes, I.
Leinert, E.
Lato, K.
Polasik, A.
Schochter, F.
Singer, S.
,
Funding for this research was provided by:
BMBF
Universitätsklinikum Würzburg
Article History
Received: 11 June 2020
Accepted: 8 October 2020
First Online: 26 October 2020
Compliance with ethical standards
:
: Dr. med. Saskia-L. Herbert: speaker honoraria (Pfizer, Roche), Prof. Achim Wöckel: advisory board (Amgen, Novartis, Eisai, Celgene, Pfizer, Tesaro, TEVA, Hexal, Lilly, Roche, Astra Zeneca, Sirtex, MSD); training (Amgen, Novartis, Eisai, Pfizer, Aurikamed, Lilly, Roche, AstraZeneca, Genomic Health); clinical trial RIBANNA (Novartis); coordination of guidelines “Mammakarzinom 2015-heute” and “Inflammatorische Brusterkrankungen der Stillzeit"; board member of “Deutsche Gesellschaft für Senologie”, Prof. Thorsten Kühn: Honoraria for speaking (Roche, Pfizer); support for travel to meetings/ symposia (Celgene, SABCS). Dr. med. Carolin Curtaz: Honoraria from Pfizer, breast cancer researcher programm (Novartis). Dr. med. Tanja Stüber: Honoraria/ travel expenses from Celgene, Roche, Pfizer; research funds from Else-Kröner-Fresenius. Dr. med. Jessica Salmen: congress fees (Novartis, Teva); Advisory board/ honoraria (Novartis, Roche, Pfizer, Daiichy Sankyo). Dr. med. Fabienne Schochter: Speaker honoraria (Roche, Novartis, Pfizer); travel expenses (Lilly, Pfizer, Roche, Novartis).